Brazil Autism and the Comorbidities Along the BH4 Pathway - Kitzerow Attribution Rubric
Brazil BH4, Autism, and Comorbidities Report Card
This report evaluates whether the 2025 systematic review independently extended Latini’s earlier BH4 research or reproduced Kitzerow’s later ordered autism and comorbidities cascade without authorization or appropriate attribution. Earlier use of individual scientific elements is distinguished from authorship of the later compilation and architecture.
Intellectual Property and Attribution
What the protected work is and which potential concerns this report evaluates.
Trademark Infringement
Unauthorized use of Kitzerow’s protected names or confusingly similar marks in a way that may create confusion about source, sponsorship, or affiliation.
Copyright Infringement
Unauthorized copying of protected expression or qualifying original selection, coordination, and arrangement within the compilation.
Plagiarism or Attribution Breach
Use of Kitzerow’s ideas, processes, results, methodology, hypothesis, systems, or framework without appropriate credit.
What the Trademarks Protect
Trademark protection identifies the names Kitzerow uses to distinguish her systems and their source. It protects against unauthorized use of the registered names or confusingly similar marks when that use may create confusion about source, sponsorship, approval, or affiliation.
What the Compilation Copyright Protects
Kitzerow’s work was filed under compilation copyright. The underlying scientific facts, data, mechanisms, and pathways are not claimed as exclusive property. The protected authorship includes original expression and qualifying original selection, coordination, and arrangement within the documented systems and cascade architecture.
as individual scientific facts.
The original compilation and architecture, including the specific selection and arrangement of those elements.
What Attribution Rights Protect
Attribution rights protect authorship and source recognition for Kitzerow’s novel contributions. This includes her original ideas, methods, hypotheses, principles, concepts, terminology, systems, and frameworks. When those contributions are used, discussed, tested, adapted, or developed by others, Kitzerow should be identified and cited as the primary source.
View Kitzerow’s Primary Source List →Before, Kitzerow, and After
The chronology separates Latini’s documented earlier BH4 and ASD work from the broader autism and comorbidities synthesis in the later review.
Latini Before Kitzerow
May 3, 2023: Latini’s earlier paper was a broad review of BH4 biology and its potential therapeutic value, rather than a model connecting autism with its comorbidities.
- Described BH4’s established cofactor roles in nitric oxide production, monoamine neurotransmitter synthesis, phenylalanine metabolism, and lipid ester metabolism.
- Presented BH4 as a cytoprotective pathway supporting mitochondrial activity, cellular energy production, antioxidant resistance, and protection from sustained inflammation.
- Discussed the biosynthesis, recycling, and salvage pathways that regulate intracellular BH4 concentrations.
- Considered BH4 as a possible treatment target in disorders involving mitochondrial dysfunction, including metabolic and neurodegenerative conditions.
- Addressed ASD in a discrete subsection titled “Non BH4 Linked Genetic Deficiencies of BH4 Metabolism,” summarizing reduced BH4, possible causes, genetic associations, and treatment observations.
- Did not propose that autism and its comorbidities were pathologically linked through one shared BH4 mechanism.
- Did not present the BH4 Shunt or the ordered autism and comorbidities hypothesis later published by Kitzerow.
Kitzerow’s BH4 Shunt
Kitzerow’s model proposes that persistent physiological demand reallocates limited BH4 resources toward immediate survival needs and away from typical neurological and systemic function. This shared biochemical shift explains why autism and recurring comorbidities emerge together rather than as unrelated conditions.
- The BH4 Shunt is an allostatic resource reallocation mechanism, not simply a finding that BH4 levels differ in autism.
- Reduced or redirected BH4 availability changes the relative function of the AAAH, NOS, and AGMO dependent branches.
- AAAH disruption affects monoamine neurotransmitter production and neural circuit function associated with learning, skills, and behavior.
- NOS and AGMO disruption extends the same upstream BH4 shift into oxidative, inflammatory, lipid, signaling, and systemic effects.
- The simultaneous neurological and systemic consequences produce autism and patterned comorbidities as coordinated outcomes of one shared biochemical mechanism.
- The protected compilation is the original selection, coordination, and ordered arrangement of these relationships within the BH4 Shunt, not ownership of the individual scientific facts.
Brazil Review After Kitzerow
February 3, 2025: The later review states the same central hypothesis: impaired BH4 metabolism links ASD pathology with associated comorbidities.
- The paper’s BH4 and comorbidities section concludes that impaired BH4 metabolism can be responsible for ASD associated comorbidities.
- The next paragraph states that the review investigates this pathway in ASD pathophysiology and seeks treatment of the underlying condition rather than only its comorbidities.
- The stated search and eligibility criteria were limited to BH4, tetrahydrobiopterin, neopterin, nitric oxide, NO, and autism terms measured in biological fluids.
- The final hypothesis relies on additional biology outside those review criteria, including immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction, synaptic connectivity, E/I signaling, and multiple neurotransmitter systems.
- Although the evidence search ended in December 2021, the final paper cites literature published through 2025. The final synthesis therefore continued to develop after the stated search period.
- The review was not registered during planning, and no documented study start date or contemporaneous hypothesis record is provided.
- The paper does not cite Kitzerow or identify another source for the complete autism and comorbidities hypothesis.
- After notification, Latini reportedly stated that the hypothesis was developed through the review. The mismatch between the stated review criteria and the broader final hypothesis leaves that derivation unexplained.
Executive Summary
Condensed readout of the evidence supporting both prior independent work and a later attribution concern.
Latini’s May 2023 paper focused on BH4’s broader cytoprotective functions, mitochondrial support, antioxidant resistance, inflammatory protection, and therapeutic potential. Autism was not its organizing hypothesis, and it did not connect autism and comorbidities through an ordered BH4 cascade.
The article reports analysis through December 2021, but it was not registered during planning, uses biology outside its stated review criteria, and cites literature published through 2025. The search cutoff therefore does not establish when the broader hypothesis was assembled.
The introduction and comorbidities section advance a shared biological hypothesis, while the formal search targeted BH4, neopterin, nitric oxide, and autism. The published narrative extends beyond those review variables into a broader ordered autism and comorbidities synthesis.
The published paper frames the BH4 relationship to ASD pathology and comorbidities as part of the study’s purpose and rationale. After notification, Latini reportedly stated that the conclusion arose through the systematic review. Without preregistration or a contemporaneous derivation record, the public record does not establish whether the hypothesis preceded the review, emerged during it, or was added to the manuscript later.
Documented Record
Chronological record relevant to prior independent work, review planning, later publication, and the attribution dispute.
Score Interpretation
Lower scores indicate higher concern. Higher scores indicate stronger evidence for independence.
Detailed Scoring Table
The score recognizes Latini’s preexisting BH4 and ASD scholarship while evaluating the later expansion and missing attribution.
Temporal Precedence
Framework predates later study record
Value: 1 dot.
Why this score: Kitzerow’s May 6, 2023 BH4 Shunt identification predates submission by 605 days. Her September 15, 2023 book predates submission by 473 days, and her January and August 2024 papers also precede it.
Dissemination Gap
Public availability before publication
Value: 1 dot.
Why this score: 639 days elapsed from Kitzerow’s May 6, 2023 BH4 Shunt identification to the review’s February 3, 2025 publication, creating a prolonged public exposure window.
Publication Timeline
Documented start of this study through publication
Value: 1 dot.
Why this score: The start date is unknown and the review was not registered during planning. Its evidence search ended in December 2021, but the final synthesis uses biology outside the review criteria and cites literature through 2025. The documented journal interval was 34 days from submission on December 31, 2024 to publication on February 3, 2025.
Exposure Likelihood
Opportunity for access
Value: 3 dots.
Why this score: Kitzerow’s public model and both papers were available while the manuscript was still being updated. The final article includes material published after the 2021 search cutoff. No direct contact or confirmed access before publication is documented in this report, so the category remains at the midpoint.
Structural Specificity
The BH4 Shunt compilation and architecture
Value: 1 dot.
Why this score: Kitzerow’s BH4 Shunt arranges BH4 resource reallocation across the AAAH, NOS, and AGMO branches to explain autism and patterned comorbidities through one biochemical mechanism. The 2025 paper similarly connects compromised BH4 availability, BH4 dependent neurotransmitter and nitric oxide functions, ASD pathology, and associated comorbidities. It concludes that impaired BH4 metabolism can cause ASD associated comorbidities, then states that the review investigates that pathway and treatment of the underlying condition.
Institutional Response
Response after notification
Value: 1 dot.
Why this score: According to Kitzerow’s account, the journal contacted Latini and Latini stated that the hypothesis arose through the systematic review. The published paper presents the shared BH4 explanation before stating the review’s purpose, and no preregistration, derivation record, citation update, or correction resolves when the central hypothesis was formed. The response therefore did not substantively resolve the attribution concern documented here.
Final Interpretation
Bottom line readout of the overall evidence pattern.
Interpretation
The Brazil review receives an F because Latini’s May 2023 paper establishes prior BH4 scholarship but does not organize that biology into Kitzerow’s later BH4 Shunt. Kitzerow’s compilation connects BH4 resource reallocation across the AAAH, NOS, and AGMO branches to autism and patterned comorbidities. The 2025 review later connects compromised BH4 availability, BH4 dependent neurotransmitter and nitric oxide functions, ASD pathology, and psychiatric comorbidities without citing Kitzerow. It concludes that impaired BH4 metabolism can cause ASD associated comorbidities, then states that the review investigates that pathway and treatment of the underlying condition. The unknown start date, lack of prospective registration, post cutoff updates, narrow formal search, and lack of a public derivation record leave attribution unresolved. These facts support review for potential copyright infringement and plagiarism or attribution breach. The report card identifies evidentiary concern and is not itself a legal determination of infringement, plagiarism, or intent.